Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Mereo BioPharma's Non-Current Assets fell 4092.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 4191.87%. This contributed to the annual value of $1.6 million for FY2024, which is 4059.88% down from last year.
  • Latest data reveals that Mereo BioPharma reported Non-Current Assets of $1.2 million as of Q3 2025, which was down 4092.93% from $1.2 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Non-Current Assets high stood at $36.5 million for Q4 2021, and its period low was $1.2 million during Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $2.2 million (2022), whereas its average is $10.1 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 9393.26% in 2022, then surged by 2360.11% in 2023.
  • Mereo BioPharma's Non-Current Assets (Quarter) stood at $36.5 million in 2021, then crashed by 93.93% to $2.2 million in 2022, then grew by 23.6% to $2.7 million in 2023, then tumbled by 40.6% to $1.6 million in 2024, then fell by 26.55% to $1.2 million in 2025.
  • Its Non-Current Assets stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.4 million for Q1 2025.